log in
Print | Back

Haynes and Boone, LLP

Kayla J. Cristales

Kayla J. Cristales

Associate

Haynes and Boone, LLP
Texas, U.S.A.

tel: +1 214.651.5827
Send an Email

Local Time: Fri. 08:40

Profile
Kayla Cristales is an associate in the Healthcare and Life Sciences Practice Group in the Dallas office of Haynes and Boone. Her practice focuses primarily on transactional and regulatory healthcare and FDA matters. While she advises clients on pure FDA matters and pure healthcare matters, her unique expertise in both areas makes her a valuable asset to the many clients whose businesses are subject to both FDA and healthcare laws, regulations, and rules, such as, for example, companies engaged in the manufacture, distribution, marketing, sale, promotion, or purchase of pharmaceuticals, biologics, or medical devices and the many ancillary activities in which such companies may be involved.

On the healthcare side, Kayla routinely advises clients on a wide range of issues involving key regulatory areas, including the Stark Law; the Anti-Kickback Statute; state fraud and abuse laws; the Sunshine Act; state examining board rules; the Administrative Procedure Act; state corporate practice of medicine prohibitions, among a number of others. In doing so, she has added critical regulatory insight to a number of transactional operations and compliance reviews and helped healthcare clients address obstacles and navigate through the often overlapping state and federal healthcare laws.

On the FDA side, Kayla has assisted with matters confronting a number of evolving FDA-regulated areas, including compliance with state and federal laws and regulations governing the marketing and/or distribution of products containing hemp-derived CBD (after the enactment of the 2018 Farm Bill). She also regularly counsels FDA-regulated clients in connection with labeling reviews; product classification analyses; manufacturing, development, commercialization, and/or supply agreement negotiation; and advertising, marketing, and other promotional communications, among many other areas.

Bar Admissions

Texas, 2017

Education

J.D., SMU Dedman School of Law, 2017, summa cum laude; Order of the Coif; SMU Law Review
B.A., The University of Oklahoma, 2012
Areas of Practice
Professional Career

Significant Accomplishments

Conduct labeling reviews of food products, dietary supplements, cosmetics, OTC drugs, and other consumer products.
Regularly provide healthcare and FDA regulatory guidance to issuers and underwriters in connection with Exchange Act filings and related activities.
Review and negotiate agreements with customers, purchasing organizations, and vendors, including product supply, purchasing, licensing, marketing, distribution, co-branding, franchising, and similar agreements.
Draft professional services agreements, such as employment, consulting, medical director, and other similar and ancillary agreements.
Draft, review, and revise research-related documents and agreements with contract research organizations, hospitals and health systems, and physician groups.
Assist with mergers and acquisitions involving healthcare and/or FDA-regulated entities.
Advise on new and existing financial relationships and interactions with healthcare providers, including speaker engagements, consulting arrangements, CME events, and gifts/dinners/travel/promotional items.
Provide regulatory and compliance advice regarding federal and state Anti-Kickback and self-referral statutes, FDA regulations, Sunshine Act and reporting and disclosure obligations, HIPAA and data privacy and security laws, and antitrust laws.
Review, develop, and provide education and training on fraud and abuse laws as well as audits and compliance program policies and procedures for FDA-regulated companies, including sales force compliance and marketing strategies.
Provide risk management counseling, including self-evaluative audits, designing corrective action plans, and handling of possible past or existing regulatory violations or events of non-compliance.
Provide guidance and crisis management during threatened or actual recalls.
Perform comprehensive state and federal regulatory analyses and provide compliance advice in connection with numerous operational endeavors proposed by healthcare entities.
Review and revise patient paperwork and internal policies for physician groups and other healthcare entities.
Provide guidance regarding provider enrollment and claim submission requirements in relation to Medicare, Medicaid, CHIP, TriCare, and Medicare Advantage.
Conduct surveys of material state laws applicable to healthcare and FDA clients, including those related to patient abandonment, informed consent, the corporate practice of medicine, data privacy, genetic testing, and hemp-derived CBD.
Advise restaurant chains and retailers regarding FDA menu labeling requirements, consumer advisory warnings, and other related matters.
Articles

It's Still Gray: The 2018 Farm Bill and the Legality of CBD Under Federal Law
Haynes and Boone, LLP, January 2019

President Trump recently signed the Agriculture Improvement Act of 2018 (also known as the 2018 Farm Bill) and the cannabis industry quickly and widely celebrated passage as clearing the way to sell products containing cannabidiol (better known as CBD). But is it really? As one might expect, this lawyer’s answer is that “it depends.”CBD has become known for its purported health benefits in relation to a wide range of conditions...

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, December 2018
Haynes and Boone, LLP, December 2018

Should States Embrace Telehealth Parity? Parity in telehealth is the notion that health services provided via telehealth technology should be treated equally as health services provided face-to-face. This is consistent with coverage parity, which requires payors to provide the same level of insurance coverage for patient encounters and services, while payment parity (a.k.a...

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, March 2018
Haynes and Boone, LLP, March 2018

 More than two and a half years after the U.S. Food and Drug Administration (FDA) announced that it was reevaluating its regulatory framework for homeopathic products, the FDA released its Draft Guidance on Drug Products Labeled as Homeopathic. The Draft Guidance summarizes the FDA’s current enforcement perspective on homeopathic products and provides a list of the FDA’s enforcement priorities.The bills reawakened a debate about the pros and cons of POHs...

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | PRIVACY POLICY | DISCLAIMER |  © World Services Group, 2020